Oslo, 7 January 2026: The announced extraordinary general meeting of Navamedic
ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") was held today at 12:00
CET. All items on the agenda were approved in accordance with the board of
directors' proposals and the nomination committee's recommendations. A copy of
the minutes from the extraordinary general meeting is attached to this notice
and will also be made available on the Company's webpage www.navamedic.com.
This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880, e-mail:
kathrine@navamedic.com
Nils Ole Krekling, CFO, Mobile: +47 924 24 016, e-mail:
nils.ole.krekling@navamedic.com
About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in Greece.
Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.